San Miguel JF. Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?. Haematologica. 2014 Jan;99(1):5-6
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.